In a study of 933 patients with non-squamous NSCLC, the findings displayed that none of the patients with MET exon 14 skipping mutation showed activating mutations in KRAS, EGFR or ERBB2, or rearrangements involving ALK, ROS1, or RET [18]. Here, KRAS is linked to non-small cell lung carcinoma.